Scailyte quarterly update
Scailyte quarterly update, highlighting the successful first closing of the Series A financing round and the three new patents filed on the discoveries. Scailyte has appointed a new Chief Operating Officer with executive pharma background, Corinne Solier. Here is a quote from Corinne – “The next revolution will be realized when we can fully harness the power of single-cell biological information to discover new and more sensitive biomarkers of diagnostic, predictive and prognostic value for individual patients. Scailyte’s perfectly suited capabilities, as well as the passionate and excellent team, convinced me to join the company, to fulfil our mission of advancing precision medicine.” Read more below:
Read our previous quarterly update here.
About Scailyte
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.
Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.
ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.
Recent News
Scailyte Extends Series A to USD 8 Million
We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...
Recent News
ScaiDigest Volume 6: Variational autoencoders (VAEs) in biology
Welcome to the 6th edition of ScaiDigest, where we explore cutting-edge research in single-cell anal...
Recent News
Pitch-nic Expo
We're excited to share that our Senior Vice President of Corporate & Technology Development, Corinne...
Recent News
Targets & Cell Types in Immuno-Oncology Europe 2023
Scailyte is part of Targets & Cell Types in Immuno-Oncology Europe 2023 event on November 14-15 in B...
Recent News
Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs
We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...
Recent News
NextGen Omics 2023
Scailyte is gearing up for NextGen Omics 2023, one of the most scientifically engaging events in Lon...
Recent News
Recent News
ScaiDigest Volume 5: Unlocking the Secrets of AML
Read Diana's insightful post and stay at the forefront of scientific advancements in the field!
Recent News
Scailyte Extends Series A to USD 8 Million
We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...
ScaiDigest Volume 6: Variational autoencoders (VAEs) in biology
Welcome to the 6th edition of ScaiDigest, where we explore cutting-edge research in single-cell anal...
Recent News
Pitch-nic Expo
We're excited to share that our Senior Vice President of Corporate & Technology Development, Corinne...
Targets & Cell Types in Immuno-Oncology Europe 2023
Scailyte is part of Targets & Cell Types in Immuno-Oncology Europe 2023 event on November 14-15 in B...
Recent News
Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs
We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...
NextGen Omics 2023
Scailyte is gearing up for NextGen Omics 2023, one of the most scientifically engaging events in Lon...
Recent News
SITC 2023
Diana Stoycheva and Julian Spagnuolo will be sharing Scailyte’s science at a poster #201, and will...
ScaiDigest Volume 5: Unlocking the Secrets of AML
Read Diana's insightful post and stay at the forefront of scientific advancements in the field!